Kexing Biopharm Co., Ltd. (SHA:688136)

China flag China · Delayed Price · Currency is CNY
30.78
+0.91 (3.05%)
Mar 10, 2026, 2:55 PM CST
46.36%
Market Cap 5.92B
Revenue (ttm) 1.54B
Net Income (ttm) 159.44M
Shares Out 198.11M
EPS (ttm) 0.81
PE Ratio 36.88
Forward PE 27.40
Dividend 0.08 (0.27%)
Ex-Dividend Date n/a
Volume 2,606,853
Average Volume 2,535,757
Open 30.28
Previous Close 29.87
Day's Range 30.04 - 30.94
52-Week Range 20.05 - 63.99
Beta 0.73
RSI 48.21
Earnings Date Mar 28, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 971
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688136
Full Company Profile

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.54 billion, an increase of 9.54% compared to the previous year's 1.41 billion. Earnings were 159.44 million, an increase of 406.47%.

Financial Statements

News

There is no news available yet.